Autosomal Recessive Hyperinsulinism Due to SUR1 (ABCC8) Deficiency

Autosomal recessive hyperinsulinism due to SUR1 deficiency is a rare genetic condition in which the pancreas makes too much insulin even when blood sugar is already low. “Autosomal recessive” means a child inherits a non-working copy of the same gene (ABCC8) from both parents. The ABCC8 gene makes a protein called SUR1, which is a part of a tiny “gate” (the KATP channel) on the surface of insulin-making beta cells in the pancreas. The KATP channel helps the cell sense sugar and decide when to release insulin. When SUR1 is missing or cannot work, the gate stays closed; the cell is over-excited and releases insulin all the time, causing recurrent low blood sugar (hypoglycemia) from birth or early infancy. Untreated, repeated low sugar can cause seizures and brain injury, so fast diagnosis and careful treatment are essential. Frontiers+2MedlinePlus+2

Autosomal-recessive hyperinsulinism due to SUR1 deficiency is a genetic disease where the pancreas releases too much insulin, even when blood sugar is low. It is caused by loss-of-function mutations in the ABCC8 gene, which makes the SUR1 subunit of the ATP-sensitive potassium (KATP) channel in pancreatic beta cells. When SUR1 does not work, the KATP channel stays closed, beta cells remain electrically active, and insulin is secreted inappropriately. This can start right after birth, cause repeated low blood sugar (hypoglycemia), and may lead to seizures or brain injury if not treated quickly. NCBI+1

There are diffuse and focal forms of HI. Diffuse disease affects the whole pancreas and is typical with biallelic (autosomal-recessive) ABCC8 mutations. Focal disease is a small overactive area; it can be cured by surgery if precisely localized. Treatment goals are to keep glucose ≥70 mg/dL (3.9 mmol/L) to protect the brain while using medicines, nutrition, and sometimes surgery tailored to the form of HI. BioMed Central+1

A special scan called 18F-DOPA PET/CT helps doctors find a focal lesion. If a single focus is removed, many children need no further treatment. Diffuse disease often needs long-term medical therapy and occasionally near-total pancreatectomy, which is palliative and can leave ongoing hypoglycemia or later diabetes. PMC+2Medscape+2

---

Other names

This condition is also known as:

• Congenital hyperinsulinism due to ABCC8

• KATP-channel hyperinsulinism (KATP-HI)

• Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) (historic term)

• SUR1-related hyperinsulinism

• Familial hyperinsulinism (ABCC8 type)
  These names all point to the same root problem: loss-of-function mutations in ABCC8 (SUR1) that disable the KATP channel and drive inappropriate insulin release. Orpha+1

---

Types

Even within SUR1 deficiency, doctors sort cases into a few useful “types” to guide testing and treatment:

1. Diffuse vs. focal disease

• Diffuse: Most common in autosomal recessive ABCC8 disease—all beta cells across the pancreas over-secrete insulin.

• Focal: A small patch of pancreas misbehaves (often due to a paternal ABCC8 mutation and a local DNA change in the baby’s pancreas). Focal disease is surgically curable. (Strictly speaking, focal lesions usually involve a single inherited paternal variant plus a somatic 11p loss, not classic biallelic recessive disease, but they’re part of the SUR1 spectrum and relevant to diagnosis). NCBI+1

2. Diazoxide-responsive vs. diazoxide-unresponsive

• Many ABCC8 loss-of-function cases are diazoxide-unresponsive (because the KATP channel they target is not working), while a minority may partially respond depending on the exact mutation. This matters because diazoxide is the first-line drug. MDPI+1

3. Genotype-based subtypes

• Null/Truncating mutations (no SUR1 made) tend to cause severe, persistent hypoglycemia.

• Missense/trafficking/gating mutations can vary—from severe to milder courses—depending on how they disrupt channel assembly or opening. OUP Academic+1

---

Causes

Because this is a genetic disease, the primary cause is biallelic (both-allele) loss-of-function mutations in ABCC8. The list below explains causal mechanisms and real-world risk factors that make this condition more likely or shape how it appears:

1. Biallelic ABCC8 loss-of-function variants—the core cause; inherited one from each parent. MDPI+1

2. Channel “gating” defects—SUR1 cannot open/close the KATP channel properly, forcing constant insulin release. PMC

3. Trafficking defects—SUR1 is made but fails to reach the cell surface, so the channel is absent. PMC

4. Null/truncating mutations—stop the protein early; usually severe, persistent disease. OUP Academic

5. Missense mutations—single-letter DNA changes that distort SUR1 function; severity varies. OUP Academic

6. Compound heterozygosity—two different faulty ABCC8 variants, one from each parent. MDPI

7. Consanguinity (parents related by blood)—increases the chance both carry the same rare ABCC8 variant. BioMed Central

8. Family history of neonatal hypoglycemia—suggests inherited ABCC8 disease, even if relatives were never tested. PMC

9. Pancreatic beta-cell over-excitability due to a nonworking KATP gate (the final common pathway). Frontiers

10. Fetal/perinatal stress revealing the phenotype—severe disease often appears at birth when glucose regulation starts. MDPI

11. Paternal ABCC8 mutation with focal 11p loss in the pancreas—yields focal SUR1-HI (surgically curable subtype). NCBI

12. Rare dominant-negative ABCC8 variants can cause HI, but classic recessive SUR1-HI is much more common. OUP Academic

13. Ethnic or regional founder variants—some communities share specific ABCC8 mutations. (Pattern reported across cohorts.) BioMed Central

14. In vitro/experimental evidence—ABCC8 knockout stem-cell models reproduce over-secretion of insulin. Nature

15. KATP channel assembly imbalance—faulty SUR1 disrupts pairing with Kir6.2 (the KCNJ11 subunit). Frontiers

16. Epigenetic/second-hit events (in focal disease) amplify insulin secretion locally. NCBI

17. Pancreatic islet hyperplasia secondary to chronic pathway activation (reported in severe diffuse disease). BioMed Central

18. Early feeding transitions after delivery can expose the underlying defect with symptomatic lows. NCBI

19. Coexisting metabolic stressors (illness, fasting) lower glucose and worsen the impact of constant insulin. NCBI

20. Medication mismatch—lack of response to diazoxide (because channels are nonfunctional) reveals SUR1-type disease. MDPI

---

Symptoms

Symptoms reflect low blood sugar and the body’s stress response. They can be subtle or severe, especially in newborns:

1. Poor feeding or trouble sucking—baby tires quickly at the breast/bottle. MDPI

2. Irritability or high-pitched cry—often during or after feeds. MDPI

3. Lethargy/sleepiness beyond normal newborn behavior. NCBI

4. Sweating and paleness—adrenergic warning signs of hypoglycemia. NCBI

5. Jitteriness or tremor—early neurologic sign of low glucose. NCBI

6. Seizures—can occur if glucose falls sharply or stays low. NCBI

7. Apnea (pauses in breathing) or cyanosis in severe episodes. MDPI

8. Hypothermia (low body temperature) in newborns. MDPI

9. Floppiness (hypotonia)—reduced muscle tone during a low. MDPI

10. Poor weight gain if frequent lows disrupt feeding. MDPI

11. Vomiting during episodes in some infants. MDPI

12. Coma in extreme untreated hypoglycemia (medical emergency). NCBI

13. Developmental delay if brain injury occurs from repeated lows. NCBI

14. Behavior changes (older children): confusion, headache, irritability with fasting or illness. NCBI

15. No ketone “backup fuel” during lows (insulin suppresses ketones), so symptoms can be more dangerous. Wikipedia

---

Diagnostic tests

A) Physical examination

1. General newborn exam during a hypoglycemic episode
   Doctors check alertness, color, tone, temperature, breathing, and feeding while measuring glucose. Finding symptoms at low glucose prompts immediate treatment and a diagnostic work-up. NCBI

2. Neurologic check
   Looking for jitteriness, seizures, floppy tone, or changes in reflexes helps gauge severity and urgency; prolonged or recurrent symptoms can suggest persistent hyperinsulinism rather than a one-time low. NCBI

3. Growth and nutrition review
   Weight gain, feeding frequency, and dehydration signs are assessed because frequent lows disrupt feeding and growth. This also guides glucose and feeding plans during evaluation. MDPI

B) Bedside/manual tests

4. Point-of-care glucose testing (finger/heel stick)
   Rapid checks confirm low sugar at the bedside and guide immediate dextrose treatment while labs are sent. Multiple low readings raise suspicion for a persistent cause like SUR1-HI. NCBI

5. “Critical sample” during spontaneous hypoglycemia
   At the moment glucose is <50 mg/dL (2.8 mmol/L), blood is drawn for insulin, C-peptide, beta-hydroxybutyrate (ketones), free fatty acids, and other markers; **detectable insulin with suppressed ketones/FFAs strongly supports hyperinsulinism. NCBI

6. Glucagon stimulation test
   An injection of glucagon during a low should raise glucose if insulin has driven sugar into tissues; a strong glucose rise supports hyperinsulinism. (This is both a rescue and a diagnostic clue.) NCBI

7. Supervised fasting test (in hospital)
   When safe and indicated, controlled fasting confirms inappropriate insulin activity: glucose falls without ketones; insulin or C-peptide can be inappropriately detectable. This helps distinguish HI from other causes. NCBI

8. Continuous glucose monitoring (CGM)
   A sensor tracks trends and catches silent lows between heel sticks. While not diagnostic alone, patterns support the diagnosis and guide treatment adjustments. MDPI

C) Laboratory & pathological tests

9. Plasma insulin during a low
   In HI, insulin can be inappropriately present when glucose is low; even “low-normal” insulin can be inappropriate if ketones and FFAs are suppressed. NCBI

10. C-peptide
    Shows endogenous insulin secretion (helps rule out accidental insulin exposure). Detectable C-peptide during a low supports HI. NCBI

11. Beta-hydroxybutyrate (ketone body)
    Insulin blocks ketone production; suppressed ketones during a low point to HI rather than other disorders. NCBI

12. Free fatty acids (FFAs)
    Insulin also blocks fat breakdown; low FFAs during a low support HI. NCBI

13. Ammonia level
    Checks for GLUD1-related “hyperinsulinism-hyperammonemia”; normal ammonia nudges the diagnosis toward KATP (ABCC8/KCNJ11) disease. MDPI

14. Acylcarnitine profile/urine organic acids
    Screens for rare fatty-acid oxidation or metabolic conditions that can cause hypoglycemia; a normal screen strengthens the HI diagnosis. NCBI

15. Genetic testing panel (blood)
    Looks for ABCC8 mutations (and related genes like KCNJ11) to confirm SUR1 deficiency and inform treatment (e.g., diazoxide response) and family counseling (recurrence risk). NCBI+1

16. Histopathology (rarely needed in diffuse disease; obtained if surgery is done)
    Microscopy can distinguish diffuse from focal disease in resected tissue. This is not a first-line test but can confirm type in surgical cases. BioMed Central

D) Electrodiagnostic & functional tests

17. Electroencephalogram (EEG)
    Used when seizures occur; shows brain activity changes from hypoglycemia and helps guide seizure management while glucose control is optimized. NCBI

18. Cardiorespiratory monitoring (in severe newborn cases)
    Tracks heart rate, oxygen saturation, and breathing during evaluation and fasting tests; helps detect apnea or stress responses during lows. (Supportive, not specific.) MDPI

E) Imaging tests

19. 18F-DOPA PET/CT (specialized scan)
    If surgery is considered, this scan helps map focal versus diffuse disease by highlighting overactive beta-cell clusters. It is a key tool to find surgically curable focal lesions in SUR1/Kir6.2 disease. BioMed Central

20. Brain MRI (if concern for injury)
    Looks for hypoglycemia-related brain injury in infants with prolonged or severe episodes; guides neurodevelopmental follow-up. NCBI

Non-pharmacological treatments (therapies & others)

Each item has a short explanation, purpose, and mechanism in simple words.

1. Immediate IV dextrose to correct low sugar
   Purpose: raise blood glucose quickly to a safe level.
   Mechanism: gives glucose directly into the bloodstream to fuel the brain while blocking further insulin release reflexes. This is first-line in hospitals when a baby presents with symptomatic hypoglycemia. Pediatric Endocrine Society+1

2. Frequent small feeds (no prolonged fasting)
   Purpose: prevent dips in sugar between meals.
   Mechanism: steady intake of carbohydrates reduces the need for the body to keep blood sugar stable during breaks, lowering the risk of hypos with inappropriate insulin. Congenital Hyperinsulinism International

3. Continuous enteral feeds via NG/G-tube (as needed)
   Purpose: deliver a constant glucose supply in infants with poor oral intake or severe HI.
   Mechanism: slow, continuous carbohydrate infusion keeps glucose steady overnight or during illness when needs are higher. Children’s Hospital of Philadelphia

4. Glucose polymer enrichment of feeds (e.g., maltodextrin; specialist use)
   Purpose: increase carbohydrate density when volumes must be limited.
   Mechanism: polymers digest to glucose more slowly and can extend time to the next fall in blood sugar. Evidence is mainly case-based; use under endocrinology dietetic guidance. jcrpe.org+1

5. Uncooked cornstarch at bedtime (selected older children)
   Purpose: prolong overnight glucose release to reduce nocturnal hypos.
   Mechanism: cornstarch digests slowly, releasing glucose over hours; typically considered in children over 1 year with specialist oversight. jcrpe.org

6. Sick-day plan (extra carbs, earlier checks)
   Purpose: prevent hypoglycemia during illness when intake falls.
   Mechanism: structured protocols increase carbohydrate delivery and monitoring frequency to match stress-related insulin dynamics. Pediatric Endocrine Society

7. Home glucose monitoring with clear targets
   Purpose: detect and treat lows early.
   Mechanism: frequent checks help maintain ≥70 mg/dL (or individualized targets per specialist guidance) and document response to therapies. Karger Publishers

8. Emergency glucagon rescue education
   Purpose: treat severe or symptomatic lows at home or in transit to care.
   Mechanism: glucagon rapidly liberates stored liver sugar when given as an injection by caregivers trained in its use. FDA Access Data

9. Feeding therapy to overcome aversion
   Purpose: improve oral intake and growth in children who fear or refuse feeds.
   Mechanism: behavioral and occupational therapy gradually rebuilds positive feeding patterns, reducing reliance on tubes or IV glucose. Children’s Hospital of Philadelphia

10. Genetic testing and counseling
    Purpose: confirm ABCC8 mutations, plan therapy (e.g., diazoxide responsiveness), and inform family risks.
    Mechanism: genotype directs expectations (KATP forms often diazoxide-resistant) and decisions about imaging or surgery. BioMed Central

11. 18F-DOPA PET/CT for focal vs diffuse mapping
    Purpose: find a focal “hot spot” that can be surgically cured.
    Mechanism: radiotracer is taken up by overactive islet cells, guiding surgeons precisely. Journal of Nuclear Medicine

12. Specialist surgical planning for focal resection
    Purpose: cure focal disease with minimal pancreatic loss.
    Mechanism: targeted partial pancreatectomy removes only the abnormal area, often ending hypoglycemia. Medscape

13. Avoidance of prolonged fasting (hospital & home protocols)
    Purpose: prevent dangerous overnight or pre-op hypoglycemia.
    Mechanism: scheduling feeds, IV dextrose, or cornstarch reduces fasting time and risk. Pediatric Endocrine Society

14. Neurodevelopmental surveillance
    Purpose: detect effects of early hypoglycemia and provide early therapies.
    Mechanism: regular assessments and early intervention support cognition and motor skills after severe neonatal hypoglycemia. Children’s Hospital of Philadelphia

15. Dietary protein with meals/snacks
    Purpose: slow glucose absorption and provide steady energy alongside carbs.
    Mechanism: mixed meals produce smoother post-meal glucose profiles and may reduce rapid drops. (Adjunct, not curative.) Karger Publishers

16. Caregiver training & written action plans
    Purpose: ensure quick, correct responses to hypoglycemia at home/school.
    Mechanism: standardized steps for “check-treat-recheck” with clear thresholds improve safety. Pediatric Endocrine Society

17. Hospital hypoglycemia bundles for newborns
    Purpose: rapid identification and treatment of persistent neonatal hypoglycemia.
    Mechanism: screening at-risk babies, timely labs, and treatment algorithms reduce delays and brain injury. PMC

18. Consider leucine-restricted diet only for GLUD1 (HI/HA) subtype
    Purpose: reduce leucine-triggered hypoglycemia in HI/HA.
    Mechanism: lowers stimulus for insulin in GLUD1 disease; not a primary strategy for ABCC8 disease. BioMed Central

19. Transition planning to school and adolescence
    Purpose: maintain safety with sports, exams, and growth.
    Mechanism: individualized plans align snacks, monitoring, and rescue supplies with daily routines. Karger Publishers

20. Shared-care with regional HI centers
    Purpose: access teams skilled in imaging, medical therapy, and surgery.
    Mechanism: centers of excellence coordinate genetics, PET mapping, and surgical expertise for best outcomes. Congenital Hyperinsulinism International

---

Drug treatments

Important: Except for diazoxide (approved for hyperinsulinemic hypoglycemia) and glucagon (approved for severe hypoglycemia), most medications below are off-label in congenital HI. Doses here reflect label information for approved indications or pediatric HI practice from reviews; individual dosing must be set by a pediatric endocrinologist.

1. Diazoxide (PROGLYCEM®) – first-line where responsive
   Class: KATP channel opener.
   Typical pediatric dose: Infants/newborns 8 mg/kg/day divided q8–12h; children/adults start 3 mg/kg/day, titrate (max 15 mg/kg/day infants, 8 mg/kg/day older) per label; stop if ineffective after 2–3 weeks.
   Time/Purpose: chronic control of hypo due to HI.
   Mechanism: keeps KATP channels open → beta cells less active → less insulin.
   Side effects: fluid retention, hypertrichosis, hyperuricemia, neutropenia, pulmonary hypertension in infants (monitor). Often ineffective in ABCC8/KCNJ11 disease. FDA Access Data+1

2. Octreotide (Sandostatin®) – off-label for HI
   Class: somatostatin analog.
   Dose/Time: label dosing varies by indication; in HI, pediatric practice uses sc infusions or divided doses (specialist titration).
   Purpose/Mechanism: binds somatostatin receptors to suppress insulin release; used when diazoxide fails.
   Side effects: GI upset, gallstones, growth effects; dosing and monitoring are specialist tasks. FDA Access Data+1

3. Lanreotide (Somatuline® Depot / Lanreotide Injection) – off-label for HI
   Class: long-acting somatostatin analog.
   Dose/Time: label for acromegaly/GEP-NETs is 120 mg deep-subcutaneous every 4 weeks; in HI, used off-label for maintenance when octreotide effective but hard to deliver.
   Purpose/Mechanism: sustained insulin suppression via SSTR binding.
   Side effects: similar to octreotide; injection-site effects. FDA Access Data+1

4. Glucagon for injection – rescue & bridging therapy
   Class: hyperglycemic hormone.
   Dose/Time: emergency rescue per label kits; in hospital, continuous low-dose infusions may be used short-term.
   Purpose/Mechanism: liberates liver glycogen → raises glucose fast during severe lows or while adjusting other therapy.
   Side effects: nausea, vomiting; use as directed by clinicians. FDA Access Data

5. Sirolimus (Rapamune®) – off-label/last-line in refractory HI
   Class: mTOR inhibitor.
   Dose/Time: label dosing is for transplant; in HI, off-label low-dose regimens with drug-level monitoring have been reported in small series.
   Purpose/Mechanism: reduces beta-cell excitability/insulin secretion via mTOR pathway modulation; reserved for severe diazoxide-unresponsive cases.
   Side effects: immunosuppression, mouth ulcers, lipids, infection risk—specialist decision only. FDA Access Data

6. Everolimus (Afinitor®/Zortress®) – off-label in selected refractory HI
   Class: mTOR inhibitor.
   Dose/Time: labeled for tumors/transplant; off-label pediatric HI use is rare and specialist-led.
   Purpose/Mechanism: similar to sirolimus—dampens pathways that favor insulin release.
   Side effects: stomatitis, infections, dyslipidemia; careful monitoring required. FDA Access Data+1

7. Nifedipine (Adalat CC®/Procardia®) – off-label, limited efficacy
   Class: calcium-channel blocker.
   Dose/Time: label is for hypertension/angina; small case reports in HI show variable benefit and it is not a reliable therapy.
   Purpose/Mechanism: reduces calcium influx in beta cells to blunt insulin exocytosis; practice has largely moved away due to poor response.
   Side effects: hypotension, flushing; not routine in modern HI care. BioMed Central+1

8. Pasireotide – off-label second-generation somatostatin analog
   Class: SSTR1–3/5 agonist (high SSTR5 affinity).
   Dose/Time: label for Cushing’s/acromegaly; in HI, early case reports show modest benefit; careful endocrine oversight needed.
   Purpose/Mechanism: potent insulin suppression via SSTR5.
   Side effects: hyperglycemia (paradoxically), GI symptoms, possible cortisol effects. e-apem.org

9. Short-term insulin (rare circumstances only)
   Class: antihyperglycemic.
   Dose/Time: very selective use (e.g., to manage stress hyperglycemia during transitions); not a routine HI treatment.
   Purpose/Mechanism: controls rebound hyperglycemia after dextrose; guided by specialists. PMC

10. Adjunctive antiemetics/acid suppression
    Purpose: support feeding tolerance when medications cause GI side effects so nutrition plans can work.
    Mechanism: symptom control to maintain intake in medically treated HI. Children’s Hospital of Philadelphia

(To keep this readable here, I’ve focused on the most commonly used/asked drugs with the best label support; other supportive medications are individualized by HI centers. Off-label use is driven by specialist experience and limited studies.) BioMed Central

---

Dietary molecular supplement concepts

There are no over-the-counter supplements that “treat” ABCC8 HI. The items below are dietetic strategies used by HI teams to shape carbohydrate delivery. Use only under pediatric endocrine/dietitian supervision.

1. Glucose polymers (maltodextrin) added to feeds
   Dose: individualized grams per kg per day in formula/feeds.
   Function/Mechanism: slow hydrolysis to glucose → extends post-feed euglycemia when volume must be limited. Evidence is case-based. jcrpe.org

2. Uncooked cornstarch (age >1 yr, specialist use)
   Dose: per dietetic plan at bedtime.
   Function/Mechanism: very slow starch digestion releasing glucose over hours → fewer night hypos. jcrpe.org

3. Higher-complex-carb base
   Dose: proportion of calories from complex carbs per plan.
   Function: steadier absorption compared with simple sugars → smoother glucose curve. Karger Publishers

4. Adequate protein with meals/snacks
   Dose: age-appropriate gram/kg targets.
   Function: slows gastric emptying and provides sustained energy to support glucose stability. Karger Publishers

5. Evening carbohydrate “top-up”
   Dose: structured bedtime snack per plan.
   Function: boosts overnight glucose availability to reduce fasting dips. Karger Publishers

6. Illness-day carbohydrate increase
   Dose: +10–20% carbohydrate during illness, as advised.
   Function: compensates for reduced intake and stress demands to prevent hypos. Pediatric Endocrine Society

7. Tube-feed formula optimization
   Dose: continuous or cycled overnight feeds.
   Function: ensures sufficient calories/carbs when oral feeds are unsafe or inadequate. Children’s Hospital of Philadelphia

8. Avoid unnecessary simple-sugar spikes
   Dose: replace frequent “sugar shots” with planned complex carbs.
   Function: prevents rebound lows from insulin overshoot after rapid sugars. Karger Publishers

9. Diet plans that avoid leucine triggers (only for GLUD1 subtype)
   Dose: targeted reduction if GLUD1 positive.
   Function: leucine restriction reduces insulin spikes; not for ABCC8 HI. BioMed Central

10. Registered dietitian follow-up
    Function: ongoing adjustment of carbohydrate type, timing, and total calories to growth and therapy changes. Pediatric Endocrine Society

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved “immunity boosters,” regenerative medicines, or stem-cell drugs for congenital hyperinsulinism due to ABCC8/SUR1. Reported mTOR inhibitors (sirolimus/everolimus) are off-label rescue options in highly selected refractory cases and carry significant risks requiring specialist oversight. Experimental cell or gene therapies are under study but not approved. Safer alternatives are the evidence-based medical, nutritional, imaging, and surgical strategies above. FDA Access Data+1

---

Surgeries

1. Focal lesionectomy (limited pancreatectomy)
   Procedure: remove only the small overactive area identified by 18F-DOPA PET/CT.
   Why: cures focal HI in most patients, often ending all treatment. Journal of Nuclear Medicine+1

2. Segmental/distal pancreatectomy (if focus near tail)
   Procedure: resect tail/body segment containing the lesion.
   Why: definitive treatment with minimal loss of normal pancreas. Medscape

3. Near-total pancreatectomy (diffuse disease, last resort)
   Procedure: remove most of the pancreas (often >95%).
   Why: palliative when diffuse ABCC8 HI is severe and unresponsive to maximal medical therapy; risks include exocrine insufficiency and later diabetes. NCBI

4. Laparoscopic approaches
   Procedure: minimally invasive resection guided by PET findings and intra-op pathology.
   Why: faster recovery, precise removal in infants/children when feasible. e-apem.org

5. Central venous access placement (supportive)
   Procedure: line insertion for safe continuous dextrose/medication infusions.
   Why: stabilizes glucose during severe phases or pre-op planning. Pediatric Endocrine Society

---

Preventions

1. Screen at-risk newborns and act early on persistent hypoglycemia. PMC

2. Keep a written home action plan with targets and rescue steps. Pediatric Endocrine Society

3. Avoid prolonged fasting; plan overnight feeds or cornstarch when advised. jcrpe.org

4. Train caregivers to use glucagon kits and check glucose correctly. FDA Access Data

5. Ensure sick-day carbohydrate plans. Pediatric Endocrine Society

6. Follow specialist nutrition to match growth and therapy. Children’s Hospital of Philadelphia

7. Use 18F-DOPA PET/CT when focal disease is suspected to allow cure. Journal of Nuclear Medicine

8. Regular developmental follow-up to mitigate long-term effects. Children’s Hospital of Philadelphia

9. Maintain multidisciplinary care with an HI center. Congenital Hyperinsulinism International

10. Educate schools and caregivers about signs of low sugar and immediate treatment. Pediatric Endocrine Society

---

When to see a doctor

Seek urgent medical care now for seizures, unconsciousness, repeated vomiting, or if blood glucose cannot be kept ≥70 mg/dL despite rescue steps. Babies with poor feeding, listlessness, jitteriness, or apnea need immediate evaluation. After discharge, arrange specialist follow-up for genetic testing (to confirm ABCC8/SUR1), imaging (to rule in/out a focal lesion), and long-term plans for feeds and medicines. Karger Publishers+1

---

What to eat & what to avoid

What to eat: regular complex-carbohydrate meals and snacks; include protein to slow absorption; use dietitian-directed glucose polymers or bedtime cornstarch in selected cases. Keep rapid-acting glucose (juice, gel) for symptoms while following your action plan. jcrpe.org+1

What to avoid: prolonged fasting, unplanned late meals, and reliance on frequent “sugar spikes” that may cause rebound lows. Do not start supplements or off-label drugs without an HI specialist—responses vary, and some medicines (e.g., nifedipine) have limited or inconsistent benefit in modern practice. BioMed Central

---

Frequently asked questions

1. Is ABCC8/SUR1 HI lifelong?
   It can be, but some children improve over time. Focal forms can be cured by surgery; diffuse forms often need long-term plans and careful follow-up. BioMed Central

2. Why doesn’t diazoxide always work?
   If the KATP channel is damaged (ABCC8/KCNJ11), the channel can’t open, so diazoxide cannot help; other options are needed. BioMed Central

3. How do doctors decide on surgery?
   They use 18F-DOPA PET/CT and genetics; focal lesions → removal; severe diffuse disease → consider near-total pancreatectomy only after maximal medical therapy. Journal of Nuclear Medicine+1

4. Is octreotide safe for children?
   It’s an off-label option; studies show many children respond, but side effects and growth/gallbladder issues require monitoring. MedNexus

5. Can lanreotide replace daily octreotide shots?
   Sometimes. Long-acting lanreotide has been used off-label after octreotide response, given every 4 weeks. BioMed Central

6. What is glucagon used for?
   As a rescue to raise sugar fast during severe lows at home or on the ward; families are trained to use it. FDA Access Data

7. Are mTOR inhibitors a cure?
   No. Sirolimus/everolimus are off-label rescue medicines for rare, refractory cases and require close monitoring for immune side effects. FDA Access Data+1

8. Can diet alone control HI?
   Diet helps, but most ABCC8/SUR1 cases need medical therapy and/or surgery. Diet is a support, not a cure. BioMed Central

9. Is cornstarch safe for infants?
   Generally considered only for children over 1 year, under specialist direction; infants typically need other strategies. jcrpe.org

10. What glucose target should we use?
    Guidelines aim for ≥70 mg/dL (3.9 mmol/L), individualized by your team to balance safety and feasibility. Karger Publishers

11. Will my child outgrow HI?
    Some improve with age; close monitoring allows safe reduction of therapies when fasting tolerance increases. BioMed Central

12. Does nifedipine help?
    Evidence is weak and inconsistent; most modern centers rarely rely on it. BioMed Central

13. What if we live far from an HI center?
    Use shared-care: local pediatricians follow the HI center’s plan; telehealth and clear action sheets help day-to-day safety. Congenital Hyperinsulinism International

14. What are the risks of near-total pancreatectomy?
    Persistent hypoglycemia, exocrine pancreatic insufficiency, and later diabetes are possible; surgeons reserve it for severe diffuse disease. NCBI

15. How do we prevent brain injury?
    Early diagnosis, keep glucose ≥70, avoid fasting, rapid rescue for lows, and systematic developmental follow-up. PMC+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 07, 2025.

PDF Documents For This Disease Condition References